"Objective response rate" trang 1 - tải miễn phí từ tailieunhanh
Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: A single-arm, phase 2 study

Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: A single-arm, phase 2 study
8    20    1
Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma
10    18    1
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study
10    43    1
Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
9    56    1
Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
10    31    1
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
8    54    1
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
8    56    1
Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma

Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma
9    45    1
Effcacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial

Effcacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial
9    14    1